El-Sherbini assumed her current role in 2012, before which she had been CEO of Al Mokhtabar since 2004. In Q1 2024, IDH recorded revenues of over $24 million, showcasing a growth of 28% YoY, and a net profit growth of 139% YoY at $8.3 million. The company officially expanded to Saudi Arabia in January 2024 through a partnership with its Jordanian subsidiary Biolab, and Izhoor Medical. El-Sherbini is also a professor of clinical pathology at Cairo University’s Faculty of Medicine.